Biological markers of Barrett’s esophagus progression to adenocarcinoma
https://doi.org/10.31146/1682-8658-ecg-177-5-91-98
Abstract
Barrett’s esophagus (BE) is a condition in which a stratifi ed squamous epithelium of the distal esophagus is replaced with a metaplastic intestinal-type columnar epithelium. BE is a precancerous condition associated with an increased risk of esophageal adenocarcinoma (EA). Current clinical practice guidelines recommend endoscopic surveillance with histological examination of esophageal biopsies for early detection of the EA. Epithelial dysplasia is the only clinically meaningful indicator of the risk for development carcinoma in BE, which is now used in practice. The existing limitations of this approach require new tools for the detection of early neoplastic disorders in BE and additional criteria to assess a risk for their progression. Within the framework of this review, the most signifi cant genetic and molecular indicators that can claim the role of diagnostic or predictive biological markers in BE are considered.
About the Authors
T. A. Karmakova
P. A. Hertsen Moscow Oncology Research Institute, branch of the Federal State Budgetary Institution “National Medical Research Radiological Center” (FSBI NMRRC), Ministry of Health of the Russian Federation
Russian Federation
Tatiana A. Karmakova, Department of Prediction of Conservative Treatment Efficiency, Leading Researcher, Dr. Sc. Biol.
Russian Federation
Tatiana A. Karmakova, Department of Prediction of Conservative Treatment Efficiency, Leading Researcher, Dr. Sc. Biol.
S. S. Pirogov
P. A. Hertsen Moscow Oncology Research Institute, branch of the Federal State Budgetary Institution “National Medical Research Radiological Center” (FSBI NMRRC), Ministry of Health of the Russian Federation
Russian Federation
Sergey S. Piogov, Endoscopy Department, Head of the Department, Dr. Sc. Med.
Russian Federation
Sergey S. Piogov, Endoscopy Department, Head of the Department, Dr. Sc. Med.
A. D. Kaprin
P. A. Hertsen Moscow Oncology Research Institute, branch of the Federal State Budgetary Institution “National Medical Research Radiological Center” (FSBI NMRRC), Ministry of Health of the Russian Federation
Russian Federation
Andrey D. Kaprin, Director-General of FSBI NMRRC, Member of RAS, Professor, Dr. Sc. Med.
Russian Federation
Andrey D. Kaprin, Director-General of FSBI NMRRC, Member of RAS, Professor, Dr. Sc. Med.
References
1. Ивашкин В.Т, Маев И.В, Трухманов А. С. и соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни // Рос. журн. гастроэнтерол. гепатол. колопроктол. – 2017. – Т. 27, № 4. – С. 75–95. Ivashkin V. T., Mayev I. V., A.s. Trukhmanov I…, Baranskaya Y. K., et al. Diagnostics and treatment of gastroesophageal ref lux disease: clinical guidelines of the Russian gastroenterological association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(4):75–95. (In Russ.) https://doi.org/10.22416/1382-4376-2017-27-4-75-95
2. ASGE guideline on screening and surveillance of Barrett’s esophagus. Gastrointest Endosc. – 2019. – Vol. 90, № 3. – Р. 335–359.
3. Gatenby P., Caygill C., Wall C., et al. Lifetime risk of esophageal adenocarcinoma in patients with Barrett’s esophagus. World J Gastroenterol. – 2014.–Vol. 20, № 28.–P. 9611–9617.
4. Falk G. W. Barrett’s oesophagus: frequency and prediction of dysplasia and cancer. Best Pract Res Clin Gastroenterol. – 2015. – Vol. 29, № 1. – Р. 125–138.
5. Whitson M.J., Falk G. W. Predictors of progression to high-grade dysplasia or adenocarcinoma in Barrett’s esophagus. Gastroenterol Clin North Am. – 2015. – Vol. 44, № 2. – P. 299–315.
6. Reid B.J., Levine D. S., Longton G., et al. Predictors of progression to cancer in Barrett’s esophagus: baseline histology and flow cytometry identify low- and high-risk patient subsets. Am J Gastroenterol. – 2000. – Vol. 95, № 7. – P. 1669–1676.
7. Duits L.C., Phoa K. N., Curvers W. L., et al. Barrett’s oesophagus patients with low-grade dysplasia can be accurately risk-stratified after histological review by an expert pathology panel. Gut. – 2015. – Vol. 64, № 5. – P. 700–706.
8. de Jonge P. J., van Blankenstein M., Looman C. W., et al. Risk of malignant progression in patients with Barrett’s oesophagus: a Dutch nationwide cohort study. Gut. – 2010. – Vol. 59, № 8. – P. 1030–1036.
9. Rugge M., Zaninotto G., Parente P., et al. Barrett’s esophagus and adenocarcinoma risk: the experience of the North-Eastern Italian Registry (EBRA). Ann Surg. – 2012. – Vol. 256, № 5. – P. 788–794.
10. Sanghi V., Thota P. N. Barrett’s esophagus: novel strategies for screening and surveillance. Ther Adv Chronic Dis. – 2019. – Vol. 26, № 10. – P. 2040622319837851.
11. Pandey G., Mulla M., Lewis W. G., et al. Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett’s esophagus. Endoscopy. – 2018. – Vol. 50, № 10. P. 953–960.
12. Caspa Gokulan R., Garcia-Buitrago M.T., Zaika A. I. From genetics to signaling pathways: molecular pathogenesis of esophageal adenocarcinoma. Biochim Biophys Acta Rev Cancer. – 2019. – Vol. 1872, № 1. – P. 37–48.
13. Abdel-Latif M.M., Duggan S., Reynolds J. V., Kelleher D. Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. – 2009. – Vol. 9. – P. 396–404.
14. Que J., Garman K. S., Souza R. F., Spechler S. J. Pathogenesis and cells of origin of Barrett’s esophagus. Gastroenterology. – 2019. – Vol. 157, № 2. – Р. 349–364.
15. Reid B. J. Early events during neoplastic progression in Barrett’s esophagus. Cancer Biomark. –2010. – Vol. 9, № 1–6. – P. 307–24.
16. Kaz A.M., Grady W. M., Stachler M. D., Bass A. J. Genetic and epigenetic alterations in Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterol Clin North Am. –2015. – Vol. 44, № 2. – P. 473–489.
17. Contino G., Vaughan T. L., Whiteman D., Fitzgerald R. C. The evolving genomic landscape of Barrett’s esophagus and esophageal adenocarcinoma. Gastroenterology. – 2017. – Vol. 153, № 3. – Р. 657–673.е1.
18. Dulak A.M., Stojanov P., Peng S. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet. – 2013.–Vol. 45, № 5.–Р. 478–486.
19. Ross-Innes C.S., Becq J., Warren A., et al. Whole-genome sequencing provides new insights into the clonal architecture of Barrett’s esophagus and esophageal adenocarcinoma. Nat Genet. 2015. – Vol. 47, № 9. – P. 1038–1046.
20. Gregson E.M., Bornschein J., Fitzgerald R. C. Genetic progression of Barrett’s oesophagus to oesophageal adenocarcinoma. Br J Cancer. – 2016. – Vol. 115, № 4. – P. 403–410.
21. Integrated genomic characterization of oesophageal carcinoma. Nature. – 2017. – Vol. 541, № 7636. – P. 169–175.
22. Nones K., Waddell N., Wayte N., et al. Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat Commun. – 2014. – Vol. 5. – P. 5224.
23. Secrier M., Li X., de Silva N., et al. Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nat Genet. – 2016. – Vol. 48, № 10. – Р. 1131–1141.
24. Fang M., Lew E., Klein M., et al. DNA abnormalities as marker of risk for progression of Barrett’s esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fi xed tissues. Am J Gastroenterol. – 2004. – Vol. 99, № 10. – P. 1887–1894.
25. Galipeau P.C., Li X., Blount P. L., Maley C. C., et al. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med. – 2007. – Vol. 4, № 2. – P. e67.
26. Altaf K., Xiong J. J., la Iglesia D. et al. Meta-analysis of biomarkers predicting risk of malignant progression in Barrett’s oesophagus. Br J Surg. – 2017. Vol. 104, № 5. – P. 493–502.
27. Чумаков П. М. Белок р53 и его универсальные функции в многоклеточном организме // Успехи биол. Химии. – 2007. – Т. 47. – C. 3–52. Chumakov P. M. Protein p53 and its universal functions in a multicellular organism. Uspekhi biol. Chemistry. 2007, vol. 47, pp. 3–52.
28. Stachler M.D., Camarda N. D., Deitrick C., et al. Detection of mutations in Barrett’s esophagus before progression to high-grade dysplasia or adenocarcinoma. Gastroenterology. – 2018. – Vol. 155. – P. 156–167.
29. Kastelein F., Biermann K., Steyerberg E. W., et al. Aberrant p53 protein expression is associated with an increased risk of neoplastic progression in patients with Barrett’s oesophagus. Gut. – 2013. – Vol. 62, № 12. – P. 1676–1683.
30. Younes M., Brown K., Lauwers G. Y., et al. P53 protein accumulation predicts malignant progression in Barrett’s metaplasia: a prospective study of 275 patients. Histopathology. – 2017. – Vol.71. – P. 27–33.
31. Davelaar A.L., Calpe S., Lau L., et al. Aberrant TP53 detected by combining immunohistochemistry and DNAFISH improves Barrett’s esophagus progression prediction: a prospective follow-up study. Genes Chromosomes Cancer. – 2015. – Vol. 54, № 2. – P. 82–90.
32. di Pietro M., Boerwinkel D. F., Shariff M. K., et al. The combination of autofluorescence endoscopy and molecular biomarkers is a novel diagnostic tool for dysplasia in Barrett’s oesophagus. Gut. – 2015. – Vol. 64, № 1. – P. 49–56.
33. Snyder P., Dunbar K., Cipher D., et al. Aberrant p53 immunostaining in Barrett’s esophagus predicts neoplastic progression: Systematic review and meta-analyses. Dig Dis Sci. – 2019. – Vol. 64, № 5. – Р. 1089–1097.
34. Fitzgerald R.C., di Pietro M., Ragunath K., et al. British Society of gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. – 2014. – Vol. 63. – P. 7–42.
35. Khara H.S., Jackson S. A., Nair S., et al. Assessment of mutational load in biopsy tissue provides additional information about genomic instability to histological classifi cations of Barrett’s esophagus. J Gastrointest Cancer. – 2014. – Vol. 45, № 2. – P. 137–145.
36. Das A., Callenberg K. M., Styn M. A., Jackson S. A. Endoscopic ablation is a cost-effective cancer preventative therapy in patients with Barrett’s esophagus who have elevated genomic instability. Endosc Int Open. – 2016. – Vol. 4, № 5. – P. E549–559.
37. Martinez P., Timmer M. R., Lau C. T., et al. Dynamic clonal equilibrium and predetermined cancer risk in Barrett’s oesophagus. Nat Commun. – 2016. – Vol. 7. – P. 12158.
38. Kailasam A., Mittal S. K., Agrawal D. K. Epigenetics in the pathogenesis of esophageal adenocarcinoma. Clin Transl Sci. – 2015. – Vol. 8, № 4. – P. 394–402.
39. Nieto T., Tomlinson C. L., Dretzke J., et al. A systematic review of epigenetic biomarkers in progression from non-dysplastic Barrett’s oesophagus to oesophageal adenocarcinoma. BMJ Open. – 2018. – Vol. 8, № 6. – P. e020427.
40. Ross-Innes C.S., Chettouh H., Achilleos A., et al. Risk stratification of Barrett’s oesophagus using a non-endoscopic sampling method coupled with a biomarker panel: a cohort study. Lancet Gastroenterol Hepatol. – 2017. – Vol. 2. – P. 23–31.
41. Katz-S ummercorn A., Anand S., Ingledew S., et al. Application of a multi-gene next-generation sequencing panel to a non-invasive oesophageal cell-sampling device to diagnose dysplastic Barrett’s oesophagus. J Pathol Clin Res. – 2017. – Vol. 3, № 4. – P. 258–267.
Review
For citations:
Karmakova T.A., Pirogov S.S., Kaprin A.D. Biological markers of Barrett’s esophagus progression to adenocarcinoma. Experimental and Clinical Gastroenterology. 2020;174(5):91-98. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-177-5-91-98
Views:
548
Email this article 